High-dose olanzapine safe against treatment-resistant schizophrenia
A new research by Louisa Gannon and colleagues offered preliminary support for the application of high-dose olanzapine in treatment-resistant schizophrenia (TRS), albeit the evidence base is limited. The findings of this study were published in Therapeutic Advances in Psychopharmacology.
Around 30% of persons with schizophrenia have treatment-resistant schizophrenia. Clozapine is the gold standard treatment for TRS, however it is not always appropriate, with some people experiencing adverse effects or being unable to participate in blood monitoring. Given the severe impact TRS may have on persons who suffer from it, different pharmaceutical approaches to treatment are required. As a result, this study was designed to undertake a literature evaluation on the effectiveness and tolerance of high-dose olanzapine (>20 mg daily) in adults with TRS.
Researchers examined PubMed/MEDLINE, Scopus, and Google Scholar for eligible studies published before April 2022. The inclusion criteria were satisfied by ten studies [five randomized controlled trials (RCTs), one randomized crossover trial, and four open label studies]. Data were collected for two primary objectives (efficacy and tolerability).
The key findings of this study were:
1. High-dose olanzapine was non-inferior to conventional therapy in four RCTs, three of which employed clozapine as the comparison.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.